JP7250689B2 - 活性化合物のための局所送達系 - Google Patents

活性化合物のための局所送達系 Download PDF

Info

Publication number
JP7250689B2
JP7250689B2 JP2019549378A JP2019549378A JP7250689B2 JP 7250689 B2 JP7250689 B2 JP 7250689B2 JP 2019549378 A JP2019549378 A JP 2019549378A JP 2019549378 A JP2019549378 A JP 2019549378A JP 7250689 B2 JP7250689 B2 JP 7250689B2
Authority
JP
Japan
Prior art keywords
oil
formulation
surfactant
gelling
polyoxyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019549378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514342A (ja
JPWO2018163176A5 (https=
JP2020514342A5 (https=
Inventor
ガルティ，ニシム
ガルティ・リーバイ，シャーロン
Original Assignee
イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド
リオトロピック デリバリー システムズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド, リオトロピック デリバリー システムズ リミテッド filed Critical イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド
Publication of JP2020514342A publication Critical patent/JP2020514342A/ja
Publication of JPWO2018163176A5 publication Critical patent/JPWO2018163176A5/ja
Publication of JP2020514342A5 publication Critical patent/JP2020514342A5/ja
Application granted granted Critical
Publication of JP7250689B2 publication Critical patent/JP7250689B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019549378A 2017-03-07 2018-03-07 活性化合物のための局所送達系 Active JP7250689B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762467863P 2017-03-07 2017-03-07
US62/467,863 2017-03-07
PCT/IL2018/050265 WO2018163176A1 (en) 2017-03-07 2018-03-07 Topical delivery systems for active compounds

Publications (4)

Publication Number Publication Date
JP2020514342A JP2020514342A (ja) 2020-05-21
JPWO2018163176A5 JPWO2018163176A5 (https=) 2022-12-27
JP2020514342A5 JP2020514342A5 (https=) 2022-12-27
JP7250689B2 true JP7250689B2 (ja) 2023-04-03

Family

ID=61692208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549378A Active JP7250689B2 (ja) 2017-03-07 2018-03-07 活性化合物のための局所送達系

Country Status (8)

Country Link
US (2) US20210137829A1 (https=)
EP (1) EP3592336A1 (https=)
JP (1) JP7250689B2 (https=)
CN (1) CN110545796A (https=)
AU (1) AU2018231842B2 (https=)
CA (1) CA3055159A1 (https=)
IL (1) IL268773B2 (https=)
WO (1) WO2018163176A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3076555B1 (fr) * 2018-01-11 2020-01-24 Jafer Enterprises R&D Sl Materiau polymerique solide impregne d'une substance organique volatile et d'un ester particulier et ses utilisations
WO2020123306A1 (en) 2018-12-14 2020-06-18 Mary Kay Inc. Cosmetic compositions
EP3986383A4 (en) * 2019-06-20 2023-07-19 Lyotropic Delivery Systems Ltd. POLYMERIC FLEXIBLE FILMS INCLUDING NANODOMAINS AND/OR A BIOACTIVE AGENT AND METHODS FOR PRODUCING THEM
CN114401770A (zh) * 2019-09-29 2022-04-26 莱雅公司 用于护理角蛋白材料的化妆品组合物
CN110960682B (zh) * 2019-12-13 2020-12-25 厦门大学 一种pH调控凝胶高压后融化态时长增强药物负载的方法
US20230113554A1 (en) * 2019-12-16 2023-04-13 Ao Technology Ag Non-stick antibiotic gels
CN111632191B (zh) * 2020-05-11 2021-12-17 西安理工大学 一种释药磷酸钙基骨水泥的制备方法
US12109290B2 (en) 2020-12-29 2024-10-08 Kao Usa Inc. Hair shine compositions
EP4112043A1 (en) * 2021-06-30 2023-01-04 GSK Consumer Healthcare SARL Nano-complex composition comprising diclofenac
CN113786382B (zh) * 2021-11-04 2024-05-28 浙江得恩德制药股份有限公司 一种盐酸特比萘芬凝胶及制备方法
EP4342450A1 (en) * 2022-09-21 2024-03-27 Haleon CH SARL Hydroalcoholic topical diclofenac formulations
EP4342449A1 (en) * 2022-09-21 2024-03-27 Haleon CH SARL Hydroalcoholic single phase gel compositions for topical delivery of diclofenac
WO2025062440A1 (en) * 2023-09-20 2025-03-27 Pulse Pharmaceuticals Pvt. Ltd Topical nano-dispersion compositions and their preparation thereof
US20250099369A1 (en) * 2023-09-27 2025-03-27 Andros Pharmaceuticals Co., Ltd. Topical delivery compositions comprising non-steroidal anti-inflammatory drugs
WO2025153330A1 (en) * 2024-01-15 2025-07-24 JeNaCell GmbH Microemulsion systems for the incorporation of poorly-water soluble compounds into bacterial cellulose
WO2025193822A1 (en) * 2024-03-13 2025-09-18 Menning Mark Michael Aqueous compositions of poorly water-soluble compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521442A (ja) 2007-03-13 2010-06-24 フューチュラ メディカル ディベロップメンツ リミテッド 局所製剤処方
JP2010529110A (ja) 2007-06-08 2010-08-26 トロイカ ファーマスーティカルズ リミテッド ジクロフェナクの新規な非水性外用溶液およびそれを調製するためのプロセス
JP2011500863A (ja) 2007-10-30 2011-01-06 ノバルティス アーゲー 局所用組成物
JP2012505909A (ja) 2008-10-16 2012-03-08 ノバルティス アーゲー 感覚成分を有する局所ｎｓａｉｄ組成物
JP2012523408A (ja) 2009-04-08 2012-10-04 カディラ・ヘルスケア・リミテッド ジクロフェナクの安定な医薬組成物
JP2015522049A (ja) 2012-07-12 2015-08-03 フェリング ベスローテン フェンノートシャップ ジクロフェナク製剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2660554B1 (fr) * 1990-04-05 1992-07-03 Oreal Composition cosmetique ou dermo-pharmaceutique aqueuse contenant en suspension des spherouides hydrates d'une substance lipidique hydrophile.
JPH06509099A (ja) 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
AU2953497A (en) 1996-05-13 1997-12-05 Novartis Consumer Health S.A. Topical composition
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
EP1598060A1 (en) 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
CN101360481A (zh) 2005-11-22 2009-02-04 雀巢技术公司 水包油乳液及其用于功能性输送的用途
EP1963270B1 (en) 2005-12-09 2009-08-05 Cerecon AG Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
WO2008058366A1 (en) 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
CN102151268B (zh) * 2011-03-28 2012-10-17 王义明 一种治疗阿尔茨海默症的复方制剂及其制备方法
CN103655459A (zh) * 2013-12-19 2014-03-26 中国药科大学 一种多功能微乳凝胶制剂及其制备工艺
CA2959601A1 (en) * 2014-09-10 2016-03-17 Novartis Ag Topical diclofenac sodium compositions
CN113788831B (zh) * 2021-10-15 2023-01-17 常州大学 二氢吲嗪并吡咯酮衍生物及类似物及其合成方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521442A (ja) 2007-03-13 2010-06-24 フューチュラ メディカル ディベロップメンツ リミテッド 局所製剤処方
JP2010529110A (ja) 2007-06-08 2010-08-26 トロイカ ファーマスーティカルズ リミテッド ジクロフェナクの新規な非水性外用溶液およびそれを調製するためのプロセス
JP2011500863A (ja) 2007-10-30 2011-01-06 ノバルティス アーゲー 局所用組成物
JP2012505909A (ja) 2008-10-16 2012-03-08 ノバルティス アーゲー 感覚成分を有する局所ｎｓａｉｄ組成物
JP2012523408A (ja) 2009-04-08 2012-10-04 カディラ・ヘルスケア・リミテッド ジクロフェナクの安定な医薬組成物
JP2015522049A (ja) 2012-07-12 2015-08-03 フェリング ベスローテン フェンノートシャップ ジクロフェナク製剤

Also Published As

Publication number Publication date
CA3055159A1 (en) 2018-09-13
US20240350401A1 (en) 2024-10-24
RU2019129711A3 (https=) 2021-06-17
AU2018231842B2 (en) 2024-03-21
AU2018231842A1 (en) 2019-09-19
IL268773B1 (en) 2023-01-01
JP2020514342A (ja) 2020-05-21
IL268773B2 (en) 2023-05-01
WO2018163176A1 (en) 2018-09-13
IL268773A (en) 2019-10-31
US20210137829A1 (en) 2021-05-13
RU2019129711A (ru) 2021-04-07
EP3592336A1 (en) 2020-01-15
CN110545796A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
JP7250689B2 (ja) 活性化合物のための局所送達系
Labie et al. Hydrogels for dermal and transdermal drug delivery
Bhaskar et al. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics
CN103442700B (zh) 含有脂质纳米颗粒和皮质类固醇或维生素d衍生物的组合物
de Araújo et al. Mucoadhesive in situ gelling liquid crystalline precursor system to improve the vaginal administration of drugs
David et al. Formulation and in vitro evaluation of ethosomes as vesicular carrier for enhanced topical delivery of isotretinoin
US9084818B2 (en) Topical dermal delivery compositions using self assembling nanoparticles with cetylated components
Bora et al. Recent advances in semisolid dosage form
Yılmaz Usta et al. Evaluation of emulgel and nanostructured lipid carrier-based gel formulations for transdermal administration of ibuprofen: Characterization, mechanical properties, and ex-vivo skin permeation
Hamed et al. Lidocaine microemulsion-laden organogels as lipid-based systems for topical delivery
ITMI20090350A1 (it) Glicerosomi e loro impiego in preparazioni farmaceutiche e cosmetiche per uso topico
Tungadi et al. Formulation, optimization, and characterization of snakehead fish (Ophiocephalus striatus) powder nanoemulgel
Kankane et al. Emulgel: A dual release system for hydrophobic drug delivery
JP2022528854A (ja) フルオロウラシル含有製剤
Mohamed et al. Tailoring of spanlastics for promoting transdermal delivery of irbesartan: In vitro characterization, ex vivo permeation and in vivo assessment
Evelyn et al. Development and evaluation of microemulsion based gel (MBGs) containing econazole nitrate for nail fungal infection
Kar et al. Formulation and evaluation of niosomal drug delivery system of ketoprofen
JP2016084340A (ja) 皮膚外用剤および皮膚バリア機能改善剤
Singh et al. Formulation development and characterization of nanoemulsion-based gel for topical application of raloxifene hydrochloride
Kamra et al. Topical liposomal gel: A review
Sangale et al. Organogel: A novel approach for transdermal drug delivery system
Ingle et al. A Brief Review Onemulgel–A Novel Topical Drug Delivery System
RU2777644C2 (ru) Системы доставки для местного нанесения для активных веществ
Al-Smadi et al. Vitamin D-loaded lipid nanoparticles: antioxidant properties, preparation, optimization, and in vitro characterization
MOURTAS et al. Liposomal gels for vaginal delivery of the microbicide MC-1220: preparation and in vivo vaginal toxicity and pharmacokinetics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220513

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7250689

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250